Last updated on March 2019

A Phase II Study of M2951 in Systemic Lupus Erythematosus (SLE)


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: SYSTEMIC LUPUS ERYTHEMATOSUS
  • Age: Between 18 - 75 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Eligible male and female subjects, aged 18 to 75 years
  • Must have diagnosis of SLE with either the Systemic Lupus International Collaborating Clinics (SLICC) criteria for SLE, or at least four of the 11 American College of Rheumatology (ACR) classification criteria for SLE, of at least six months duration prior to Screening
  • SLEDAI-2K total score greater than or equal to (>=) 6 (including clinical SLEDAI greater than or equal to (>=) 4) at Screening Visit
  • And be positive for anti-double-stranded Deoxyribonucleic Acid (DNA) and/or anti-nuclear antibody (ANA greater than or equal to (>=) 1:80) and/or anti-Smith (anti-Sm) antibody at the time of Screening
  • Other protocol defined inclusion criteria could apply.

Exclusion Criteria:

  • Subjects are not eligible for this study if they have active, clinically significant interstitial lung disease or pulmonary arterial hypertension
  • Proteinuria (urine protein to creatinine ratio [UPCR] > 4 mg/mg)
  • Acutely worsened renal function
  • Central nervous system SLE
  • Or within two weeks prior to Screening or during Screening: use of oral corticosteroids greater than (>) 30 mg daily prednisone equivalent
  • Use of injectable corticosteroids, or change in dose of corticosteroids.
  • Other protocol defined exclusion criteria could apply.

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.